Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac function and NT-proBNP in patients with chronic heart failure and left ventricular dysfunction not treated with a beta-blocker. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.

Trial Profile

Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac function and NT-proBNP in patients with chronic heart failure and left ventricular dysfunction not treated with a beta-blocker. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Aladorian (Primary)
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Aug 2012 Planned end date changed from 29 Jun 2011 to 16 Oct 2012 as reported by European Clinical Trials Database record.
    • 28 Jul 2012 Additional trial locations (Latvia and Estonia) identified as reported by European Clinical Trials Database.
    • 27 Jun 2011 This trial is recruiting at all locations according to the European Clinical Trials Registry Record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top